The diazonium salt of 3-(4-aminophenyl)-2-methyl-3H-quinazolin-4-one (2a) and its 6-bromo derivative 2b reacted with some active methylene compounds, namely ethyl acetoacetate (3), ethyl cyanoacetate (4) and acetylacetone (5), to afford the corresponding hydrazono quinazolinone derivatives 6-8. Treatment of 6a,b with hydrazine hydrate or phenyl hydrazine in refluxing ethanol afforded the corresponding pyrazolin-5-one derivatives of 3H-quinazolin-4-one 9a-d. Cyclization of 7a,b with hydrazine hydrate yielded the corresponding products 10a,b. Reaction of 8a,b with phenyl hydrazine or with urea afforded the corresponding derivatives 11a,b and 12a,b, respectively. Compounds 6-12 were identified by C,H,N analysis, IR, 1 H-NMR, 13 C-NMR and mass spectroscopy.
Introduction
3H-Quinazolin-4-ones and their derivatives have been reported to possess significant activity as antihypertensive [1] , antifibrillatory, choleretic, antiphlogistic [2] , antimitotic anticancer [3] , antifungal [4, 5] and anticonvulsant agents [6] . They have also been successfully tested as CNS depressants [7] , muscle relaxants [8] and for their antineoplastic activity [9] . On the other hand, various therapeutic activities have been reported for both pyrazole [10] [11] [12] as well as pyrimidine moieties [13, 14] . As a part of our continued program on the chemistry of 3H-quinazolin-4-one ring systems, we recently developed a simple and efficient approach to a wide range of such derivatives [15] [16] [17] [18] [19] [20] . These results prompted us to synthesize a series of novel 3H-quinazolin-4-one derivatives containing a pyrazolinone, pyrazole or pyrimidinone ring, with the aim of obtaining some novel heterocyclic systems with potentially enhanced biological properties.
Results and Discussion
3-(4-Aminophenyl)-2-methyl-3H-quinazolin-4-one (1a) and its 6-bromo derivative 1b were prepared according to the literature procedures [21, 22] . The diazonium chlorides 2a,b were synthesized by diazotisation of 1a,b using a mixture of sodium nitrite and HCl at 0-5 o C. The diazonium salts thus obtained were treated in ethanol in the presence of sodium acetate with calculated amounts of some active methylene compounds, namely ethyl acetoacetate (3), ethyl cyanoacetate (4) and acetylacetone (5) to afford the corresponding hydrazono derivatives 6-8 (Scheme 1). Compounds 6-8 were characterized by their elemental analysis, IR, 1 H-NMR, 13 C-NMR and MS data (see Experimental). For example, the IR spectrum of 6a shows an absorption band at 3431 cm - Hydrazono derivatives 6a,b were cyclized with hydrazine or phenyl hydrazine in boiling ethanol was expected to lead to the formation of the corresponding pyrazolin-5-one derivatives of 3H-quinazolin-4-one 9a-d (Scheme 2). The structures of the new compounds 9a-d were confirmed by analytical data, IR, 1 H-NMR, 13 C-NMR and mass spectra (see Experimental). Their IR spectra showed the disappearance of the characteristic bands of the acetyl carbonyl group and carboxylic acid ester and the appearance of strong bands in the 3325-3458 cm -1 region, attributed to NH group stretching and the bands of the quinazolinone and pyrazolinone ring C=O groups appearing at 1674 and 1680 cm -1 , . The mass spectrum of 11a showed a M + 1 peak at m/z 435, a peak at m/z 434 assigned to the molecular ion, a peak at m/z 264 assigned to 3-(4-diazenyl-phenyl)-2-methyl-3H-quinazolin-4-one and a peak at m/z 171 corresponding to 3,5-dimethyl-1-phenyl-pyrazole (see Experimental).
Scheme 4
12a X = H 12b X = Br
Reaction of the hydrazono derivatives 8a,b with urea in ethanol under reflux conditions for 5 hours gave solid products of molecular formula C 21 H 18 N 6 O 2 , which may be formulated as 12a, or C 21 H 17 BrN 6 O 2 , corresponding to the bromo derivative 12b, respectively (Scheme 4). Compound 12a displayed bands in the IR spectrum at 3424 (NH), 1676 (quinazolin-4-one C=O), 1592 (pyrimidin-2-one C=O) cm -1 . Structure 12a was also indicated by the 13 C-NMR spectra which provided conclusive evidence for the quinazolin-4-one and pyrimidin-2-one structures. Thus, it showed signals at δ 152.3, 160.6, 120.5, 126.1, 125.3, 133.8, 126.6 and 145.4 (quinazolin-4-one C-2, C-4, C-4a, C-5, C-6, C-7, C-8 and C-8a, respectively) and at δ 157.3, 165.7, 149.7 and 166.7 (pyrimidin-2-one C-2, C-4, C-5 and C-6 respectively). The 13 C-NMR data were assigned based on the comparison of the data obtained for 12a with those reported in the literature for 3H-quinazolin-4-one [23] and pyrimidin-2-one [24] ring systems.
Experimental

General
Melting points were determined on an Electrothermal MEL-TEMP II melting point apparatus and are reported uncorrected. IR spectra were recorded on a Unicam SP 1200 spectrophotometer using KBr discs. 1 
Diazotization of 6-substituted 2-methyl-3-(4-aminophenyl)-3H-quinazolin-4-ones 1a,b.
A mixture of 1a or 1b (0.01 mole) in concentrated HCl (3 ml) was cooled to 0 -5 o C under ice, and cooled sodium nitrite solution (1.5 g in 10 mL of water) added to it dropwise during 10 minutes. The reaction mixture was then stirred for 30 minutes.
General procedure for the preparation of hydrazono derivatives 6-8
To an ice-cold mixture of the appropriate active methylene compound (ethyl acetoacetate, ethyl cyanoacetate or acetylacetone) (0.01 mole) and sodium acetate (4.10 g; 0.05 mole) in ethanol (50 mL), was added dropwise with stirring a solution of diazonium salt compound 2a or 2b (0.01 mole) over 15 minutes. The stirring was continued for 30 minutes and the reaction mixture then left for 2 hours at room temperature. The solid product was collected and recrystallized from ethanol to give the corresponding hydrazono derivatives 6-8. The following hydrazones were prepared in this manner: 
2-{[4-(2-Methyl-4-oxo-4H-quinazolin-3-yl)-phenyl]hydrazono}-3-oxo-butyric acid ethyl ester (6a
2-{[4-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-phenyl]hydrazono}-3-oxo-butyric acid ethyl ester (6b
Cyano-{[4-(2-methyl-4-oxo-4H-quinazolin-3-yl)-phenyl]hydrazono}acetic acid ethyl ester (7a
{[4-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-phenyl]hydrazono}cyano-acetic acid ethyl ester (7b
3-{[4-(2-Methyl-4-oxo-4H-quinazolin-3-yl)phenyl]hydrazono}-pentane-2,4-dione (8a
3-{[4-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)phenyl]hydrazono}-pentane-2,4-dione (8b
General Procedures for the Cyclization Reactions Method A: With Hydrazine Hydrate
A mixture of the appropriate 6a,b or 7a,b (0.005 mole) and hydrazine hydrate (0.32 mL, 0.01 mole) in ethanol (30 mL) was heated under reflux for 4-6 hours. The solvent was concentrated and the reaction product was allowed to cool. The separated product was filtered off, washed with water, dried and recrystallized from ethanol. The following title compounds were prepared as just described: 
2-Methyl-3-{4-[N′-(3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene)hydrazino] phenyl}-3H-quinazolin-4-one (9a)
.
6-Bromo-2-methyl-3-{4-[N′-(3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene)hydrazino]phenyl}-3H-quinazolin-4-one (9b
3-{4-N′-(3-Amino-5-oxo-1,5-dihydropyrazol--4-ylidene)hydrazino]phenyl}-2-methyl-3H-quinazolin-4-one (10a
Method B: With Phenyl Hydrazine
To a solution of the appropriate 6a,b or 8a,b (0.01 mole) in glacial acetic acid (30 mL) was added phenyl hydrazine (1.30 g, 0.012 mole) and anhydrous sodium acetate (0.82 g, 0.01 mole). The reaction mixture was heated under reflux for 4 hours. The mixture was poured into ice-cold water and stored in a refrigerator. The crude product, which separated, was washed with water, dried and recrystallized from methanol. The following title compounds were prepared as just described: 
2-Methyl-3-{4-[N′-(3-methyl-5-oxo-1-phenyl-1,5-dihydropyrazol-4-ylidene)hydrazino]phenyl}-3H-quinazolin-4-one (9c
Method C: With Urea
A mixture of hydrazono derivatives 8a,b (0.005 mole) and urea (0.6 g, 0.01 mole) in ethanol (40 mL) was heated under reflux for 5 hours. After cooling to room temperature, crushed ice was added and the mixture was stirred for 1 hour. The separated product was collected by filtration and recrystallized from aqueous ethanol. The following title compounds were prepared as just described: 
3-{4-[N′(4,6-Dimethyl-2-oxo-2H-pyrimidin-5-ylidene)hydrazino]phenyl}-2-methyl-3H-quinazolin-4-one (12a
6-Bromo-3-{4-[N′(4,6-dimethyl-2-oxo-2H-pyrimidin-5-ylidene)hydrazino]phenyl}-2-methyl-3H-quinazolin-4-one (12b
